Sutro to receive a $90M up front to develop iADCs for 3 biological targets & will be eligible to receive ~$422.5M per candidate in milestones along with royalties & will lead the research & preclinical studies while Astellas will lead the clinical development
Sutro gets an option to share costs & profits to develop & commercialize product candidates in the US. If Sutro exercises an option, the costs of co-development & co-commercialization, profits/losses will be split equally b/w the 2 companies
The collaboration will combine Sutro’s ability with Astellas’ oncology R&D expertise to expand iADC development to treat cancer & boost anti-cancer activity, providing new options to patients who do not respond to existing cancer immunotherapies
Ref: Sutro Biopharma | Image: Astellas
